Mickael Löthgren

Learn More
There is a fairly poor evidence base available on cost of substance abuse in Europe, where the most recent studies are performed in the middle of the 1990s, and cover only the major European countries and the Nordic region. There is little coherence in methodology across studies, which makes comparison of cost results across studies less viable. However,(More)
pression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 164:665-673 9. Creed F, Morgan R, Fiddler M, Marshall S, Guthrie E, House A (2002) Depression and anxiety impair health-related quality of life and are associated with increased costs in general medical inpatients. Psychosomatics 43:302-309 10. Hertzman(More)
To estimate changes in resource usage, hospitalization rates, and costs in actual practice in Sweden for schizophrenia patients after switching to long-acting injectable risperidone (Risperdal Consta). A retrospective chart review within-subject mirror-image study using actual practice chart review data was used to compare annual hospital bed-days and(More)
INTRODUCTION Little is known regarding healthcare costs for HIV/AIDS patients in the era of highly active antiretroviral therapy (HAART) and subgroups of patients according to the severity and progression of HIV infection in Sweden. The objective of this study is therefore to describe the direct medical resource use and cost of healthcare for HIV patients(More)
BACKGROUND Few direct head-to-head comparisons have been conducted between drugs for the treatment of diabetic peripheral neuropathic pain (DPNP). Approved or recommended drugs in this indication include duloxetine (DLX), pregabalin (PGB), gabapentin (GBP) and amitriptyline (AMT). We conducted an indirect meta-analysis to compare the efficacy and(More)
No consensus has yet been reached on how to analyse uncertainty in economic evaluation studies where individual patient data are available for costs and health effects. This paper summarises the available results regarding the analysis of uncertainty on the cost-effectiveness plane and argues for using the net-benefit approach when analysing uncertainty in(More)
BACKGROUND Two phase II trials (POWER 1 and 2) have demonstrated that darunavir co-administered with low-dose ritonavir (DRV/r) provides significant clinical benefit compared with control protease inhibitors (PIs) in highly treatment-experienced, HIV-1-infected adults, when co-administered with optimized background therapy (OBR). OBJECTIVE To determine(More)
Objectives. Quantify changes in hospital resource use in Finland following initiation of risperidone long-acting injection (RLAI). Materials and Methods. A retrospective multi-center chart review (naturalistic setting) was used to compare annual hospital bed-days and hospital episodes for 177 schizophrenia patients (mean age 47.1 years, 52% female, 72%(More)